Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
2016; Elsevier BV; Volume: 389; Issue: 10068 Linguagem: Inglês
10.1016/s0140-6736(16)32621-6
ISSN1474-547X
AutoresAna María Henao-Restrepo, Anton Camacho, Ira M. Longini, Conall Watson, W. John Edmunds, Matthias Egger, Miles W. Carroll, Natalie E. Dean, Ibrahima Diatta, Moussa Doumbia, Bertrand Draguez, Sophie Duraffour, Godwin Enwere, Rebecca F. Grais, Stephan Günther, Pierre-Stéphane Gsell, Stefanie Hossmann, Sara Viksmoen Watle, Mandy Kader Kondé, Alpha Kabinet Keïta, Souleymane Kone, Eewa Kuisma, Myron M. Levine, Sema Mandal, Thomas Mauget, Gunnstein Norheim, Ximena Riveros, Aboubacar Soumah, Sven Trelle, Andrea Vicari, John-Arne Røttingen, Marie‐Paule Kieny,
Tópico(s)Global Security and Public Health
ResumorVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa.
Referência(s)